1 Min Read
March 22 (Reuters) - Sunesis Pharmaceuticals Inc
* Sunesis pharmaceuticals announces submission of responses to ema day 180 list of outstanding issues for marketing authorization application for vosaroxin
* Sunesis pharmaceuticals inc - "anticipating a chmp decision by mid-year"
* Sunesis pharmaceuticals - continue to work to qualify "best pharma partner" to work with us on european market launch of vosaroxin in h2 of 2017 Source text for Eikon: Further company coverage: